Fulcrum Therapeutics (FULC) Invested Capital (2019 - 2026)
Fulcrum Therapeutics (FULC) has disclosed Invested Capital for 7 consecutive years, with $349.0 million as the latest value for Q4 2025.
- Quarterly Invested Capital rose 43.6% to $349.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $349.0 million through Dec 2025, up 43.6% year-over-year, with the annual reading at $349.0 million for FY2025, 43.6% up from the prior year.
- Invested Capital for Q4 2025 was $349.0 million at Fulcrum Therapeutics, up from $198.4 million in the prior quarter.
- The five-year high for Invested Capital was $349.0 million in Q4 2025, with the low at $110.9 million in Q2 2021.
- Average Invested Capital over 5 years is $224.6 million, with a median of $225.0 million recorded in 2022.
- The sharpest move saw Invested Capital soared 122.25% in 2021, then fell 27.9% in 2024.
- Over 5 years, Invested Capital stood at $211.5 million in 2021, then decreased by 5.95% to $198.9 million in 2022, then rose by 18.22% to $235.2 million in 2023, then grew by 3.33% to $243.0 million in 2024, then surged by 43.6% to $349.0 million in 2025.
- According to Business Quant data, Invested Capital over the past three periods came in at $349.0 million, $198.4 million, and $214.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.